We observed that TfR‐targeted MAP‐CPT nanoparticles significantly slowed tumor growth in the brain and demonstrated increased accumulation in brain metastases relative to free drug and nontargeted nanoparticles. The gene discussed is TFRC; the disease is neoplasm.